Literature DB >> 15464836

Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.

Alexandra Schäfer1, Hal P Bogerd, Bryan R Cullen.   

Abstract

In cells infected by HIV-1 mutants lacking a functional Vif protein, APOBEC3G is specifically packaged into progeny virions and then interferes with the process of virus infection. Here, we show that incorporation of APOBEC3G into HIV-1 virions is mediated by the specific interaction of APOBEC3G with the carboxy-terminal nucleocapsid/p6 domain of the Gag polyprotein precursor. As a result, HIV-1 virus-like particles that lack the nucleocapsid domain fail to package APOBEC3G. Surprisingly, RNA was also found to be essential for formation of the nucleocapsid--APOBEC3G complex in vitro, thus raising the possibility that RNA may form a bridge between these two proteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15464836     DOI: 10.1016/j.virol.2004.08.006

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  139 in total

1.  Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions.

Authors:  Wenyan Zhang; Juan Du; Kevin Yu; Tao Wang; Xiong Yong; Xiao-Fang Yu
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

Review 2.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

3.  The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.

Authors:  Marcel Ooms; Susan Majdak; Christopher W Seibert; Ariana Harari; Viviana Simon
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

Review 4.  Function of a retrotransposon nucleocapsid protein.

Authors:  Suzanne B Sandmeyer; Kristina A Clemens
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

5.  The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication.

Authors:  Xiaoxia Wang; Zhujun Ao; Liyu Chen; Gary Kobinger; Jinyu Peng; Xiaojian Yao
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

Review 6.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  A multi-scale mathematical modeling framework to investigate anti-viral therapeutic opportunities in targeting HIV-1 accessory proteins.

Authors:  Gajendra W Suryawanshi; Alexander Hoffmann
Journal:  J Theor Biol       Date:  2015-09-16       Impact factor: 2.691

8.  CBFβ enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G.

Authors:  Eri Miyagi; Sandra Kao; Venkat Yedavalli; Klaus Strebel
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

9.  Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation.

Authors:  Hal P Bogerd; Bryan R Cullen
Journal:  RNA       Date:  2008-05-02       Impact factor: 4.942

10.  Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.

Authors:  Hal P Bogerd; Rebecca L Tallmadge; J Lindsay Oaks; Susan Carpenter; Bryan R Cullen
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.